BWX Technologies, Inc. Q2 FY2025 Earnings Call
BWX Technologies, Inc. (BWXT)
Call artefacts
Call audio is not captured yet.
A slide deck is not captured yet.
Transcript
Auto-generated speakersLadies and gentlemen, welcome to BWX Technologies Second Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. I would now like to turn the call over to our host, Chase Jacobson, BWXT's Vice President of Investor Relations. Please go ahead, sir.
Thank you. Good evening, and welcome to today's call. Joining me are Rex Geveden, President and CEO; and Mike Fitzgerald, Senior Vice President and CFO. On today's call, we will reference the second quarter 2025 earnings presentation that is available on the Investors section of the BWXT website. We will also discuss certain matters that constitute forward-looking statements. These statements involve risks and uncertainties, including those described in the safe harbor provision found in the investor materials and the company's SEC filings. We will frequently discuss non-GAAP financial measures, which are reconciled to GAAP measures in the appendix of the earnings presentation that can be found on the Investors section of the BWXT website. I would now like to turn the call over to Rex.
Thank you, Chase, and good evening to all of you. First, I would like to welcome Mike Fitzgerald, our CFO, to the call. Mike has been with BWXT since 2022 and previously held the roles of Chief Accounting Officer, Head of Finance and CFO of Government Operations. He is deeply ingrained in our business, is a trusted resource for the entire executive team, and I'm happy to have him on the call with us today. Now turning to our results and a discussion of our markets and outlook. Second quarter financial results exceeded our expectations, driven by strong execution and pacing of work in Government Operations. Our second quarter financial results featured double-digit adjusted EBITDA and earnings per share growth and robust free cash flow. We closed the acquisition of Kinectrics in May. Kinectrics brings a workforce of over 1,300 employees and significantly broadens our life of plant services capabilities in the nuclear power and energy infrastructure markets, enabling us to offer an even broader range of services to the market. Demand across the global security, clean energy, and medical end markets is accelerating. Backlog grew to $6 billion, up 23% quarter-over-quarter and 70% year-over-year with growth in both segments. Organic book-to-bill was 2.2% in the quarter and the pipeline of new opportunities in government and commercial operations is expanding. Turning to segment results and market outlook. Government Operations revenue was up 9% and adjusted EBITDA up 23%, exceeding our expectations. Results were driven by strong execution, particularly within the special materials portfolio, the A.O.T. acquisition, and timing of material procurement. The Naval Propulsion business is focused on driving operational excellence and maintaining production pace on our franchise, submarine, and aircraft carrier programs. As we announced last month, we signed the next pricing agreement for naval nuclear reactor components, valued at $2.6 billion over the next eight years, primarily related to Virginia and Columbia class submarines and certain components for Ford-class aircraft carriers. We booked over $1 billion in orders on this contract in the second quarter, driving Government Operations backlog to $4.4 billion, up 24% sequentially and up 55% compared to the second quarter of last year. This contract follows a $2.1 billion pricing agreement we signed in late 2024, which, combined with the administration's focus on naval shipbuilding and the submarine industrial base, supports our longer-term forecast of a 3% to 5% revenue CAGR in this line of business. Special Materials remains one of the most exciting growth stories at our company. We had strong performance on legacy contracts during the quarter, and our growth prospects are brightening. The experience of qualifications and unique licenses we possess are well matched with national security missions and position us to satisfy strategic priorities for our customers. We have nearly completed the one-year engineering study for defense uranium enrichment using the DUECE technology to satisfy naval fuel and national security needs under contract to the NNSA. Our current focus is responding to the sole source RFP issued in April for the next phase of this program, which includes design, licensing, and construction of the pilot plant. Additionally, we are working with the NNSA on long-term production of high-purity depleted uranium in quantities that exceed our business case expectations for the A.O.T. acquisition. We are also tracking several advanced nuclear fuel opportunities intended for defense and commercial applications. We will keep you posted as these prospects take shape. In microreactors, we began manufacturing the reactor core for Pele, a land-based transportable microreactor. Pele has received strong support in recent government funding bills and is highly aligned with the President's National Security Executive Order titled Deploying Advanced Nuclear Reactor Technologies, which directs the DoD to commence operations of a nuclear reactor by September 2028. As Pele progresses and the advanced fuel supply chain grows, there are multiple emerging opportunities that BWXT is well-positioned to capture. Technical Services results are strong in both operational performance and contract wins. Operating income from this business line was up over 20% compared to the average quarterly rate over the last year, and we are on track to outpace that growth for the full year. This is driven by the ramp of Pantex in Hanford, both of which began in 2024, and newer projects such as West Valley and the Strategic Petroleum Reserve, the latter of which is expected to commence in the second half of the year. From a new business perspective, Atomic Energy Canada Limited selected Nuclear Laboratory Partners of Canada, a BWXT-led joint venture, which also includes Kinectrics, to manage and operate Canadian Nuclear Laboratories, our first international project in this line of business. The annual contract value is about CAD 1.2 billion with an initial term of six years and extensions for up to 20 years. We are in the preferred bidder period and expect to transition to a contract start date late in the third quarter. Turning to Commercial Operations, reported revenue growth was 24%. On an organic basis, revenue was down 3% and largely in line with our expectation as double-digit growth in medical was offset by a modest decline in commercial power due to the timing of outage and maintenance projects, as we discussed last quarter. Backlog in the segment grew to $1.6 billion, including about $240 million from the Kinectrics acquisition. On an organic basis, book-to-bill in the quarter was 1.3. Importantly, this was driven by a multitude of contracts for existing nuclear power infrastructure, highlighting the strong underlying base of revenue in our portfolio and supporting our full year outlook for mid-teens organic growth and over 50% growth, including contribution from Kinectrics. BWXT Medical delivered a solid quarter with double-digit revenue growth driven by the PET diagnostic product lines and TheraSphere. Robust demand signals for the diagnostic and therapeutic isotopes support the outlook for over 20% growth this year. In product development, the Canadian Nuclear Safety Commission approved the irradiation of deuterium-90 and lutetium-177 using the target delivery system with Laurentis Energy Partners at the Darlington site. Regarding Tc-99, as we discussed last quarter, we've been perfecting the product attributes. Encouragingly, we have a line of sight to address the final technical issues that are typical in the scale of an industrialization phase of complex projects, and I'm quite encouraged by our progress. Given the timing, I don't expect the product launch this year; the customer appetite remains strong, and this will be an important addition to our fast-growing portfolio of medical isotopes. Turning now to commercial power, where demand is accelerating rapidly. In the CANDU market, we have talked in depth about the opportunities in the ongoing life extensions and the potential for large-scale new builds. Ontario Power Generation and Bruce Power are evaluating options to expand their nuclear reactor fleets to meet increasing electricity demand in the region. While these projects are in the planning stages, BWXT and Kinectrics are trusted partners in the Canadian nuclear market and are engaging with these utilities now. For the AP1000, we are bidding on component engineering and manufacturing contracts across a global opportunity set. There continues to be good momentum in the SMR market. In July, the NRC accepted TVA's construction permit application to build a GE Hitachi BWRX-300 at Clinch River in Tennessee, with the review expected to be complete by the end of next year. This would be a giant step in the U.S. SMR market and would complement the progress in Canada at the Darlington site, where BWXT is manufacturing the reactor pressure vessel and other important components. In addition to our work with GE and Hitachi, we are also working with TerraPower, Rolls-Royce, and others as we anticipate multiple follow-on orders in the coming years. Our long history of manufacturing large complex nuclear components and expanding capacity position us as a super merchant supplier to the SMR market. With that, I will now turn the call over to Mike.
Thank you, Rex, and good evening, everyone. Very happy to be here. I've had a chance to meet with a number of you recently, and I look forward to meeting with more of you in the coming months. I'll start with some total company financial highlights on Slide 4 of the earnings presentation. Second quarter revenue was $764 million, up 12%, with growth in both segments. Excluding contributions from acquisitions, organic revenue was up 4%. Adjusted EBITDA was $146 million, up 16% year-over-year, driven by robust double-digit growth in government operations, which was partially offset by lower adjusted EBITDA in commercial operations. Corporate expense was lower compared to last year, and we continue to expect corporate adjusted EBITDA expense in 2025 to be slightly lower than the $16.8 million reported last year. Adjusted earnings per share were $1.02, up 24%, driven by strong operating performance, complemented by a lower tax rate, foreign currency gains, and higher pension income, which were partially offset by higher interest expense due to debt associated with the Kinectrics and A.O.T. acquisitions. Our adjusted effective tax rate was 20% for the quarter, which was lower than anticipated due to various tax credits as well as higher stock compensation expense. Given the lower second quarter tax rate, we now expect our full-year tax rate to be approximately 21%. This yields a second half tax rate of approximately 22.5%, which is more in line with our expectation of our tax rate going forward. Free cash flow in the quarter was a robust $126 million, driven by good working capital management. Capital expenditures in the quarter were $33 million or 4.3% of sales due to timing of growth investments being more back half weighted during the year. We now expect capital expenditures to be 5.5% to 6% of sales for the year, driven by investments to meet growing end market demand, including the ongoing expansion of our Cambridge commercial nuclear manufacturing facility and infrastructure investments related to defense fuels and government operations. Moving now to segment results on Slide 6. In government operations, second quarter revenue was up 9%, driven by growth in naval propulsion, timing of material procurements, special materials performance, and just over 2% contribution from the A.O.T. acquisition. Adjusted EBITDA was up 23% year-over-year to $133 million, yielding an adjusted EBITDA margin of 22.6%. This was driven by favorable mix, strong operating performance, and favorable contract performance in our special materials portfolio. We continue to expect government operations to generate mid-single-digit revenue growth in 2025. However, with stronger margin performance in the first half, we now anticipate an adjusted EBITDA margin to be approximately 20.5% for the year. Turning to commercial operations, revenue was $176 million, up 24% year-over-year driven by the contribution from the Kinectrics acquisition and double-digit growth in Medical, which was partially offset by a modest decline in commercial power, as Rex discussed. Excluding Kinectrics, organic revenue was down 3%. Specific to commercial power, while we had strong revenue growth in components work on the BWRX-300 reactor pressure vessel and Pickering steam generators, this was more than offset by the expected decline in field services due to timing of key outage and maintenance projects during the year. Adjusted EBITDA in the segment was $16 million, compared to $23 million last year. This resulted in an adjusted EBITDA margin of 9.2%. While we had solid margin performance in commercial power components and fuel, this was offset by the decline in field services and growth investment to match the robust market demand. To provide some additional perspective, within Commercial Power, field services, one of our higher-margin business lines, was just over 10% of revenue in the quarter, down from over 35% in the same period last year. This unfavorable mix accounted for over half of the year-over-year margin decline, with the remainder due to unfavorable absorption of higher SG&A given lower revenue in the quarter. At the segment level, we now expect commercial operations revenue to grow over 50% with mid-teens organic growth, complemented by the Kinectrics acquisition. However, adjusted EBITDA margin is expected to be 13.5% to 14% compared to the low end of 14% to 15% previously due to growth investment and modestly higher contribution from Kinectrics. Still, our guidance implies significantly improved results in the second half of the year with higher revenue, more favorable mix, and the absence of commodity price pressure that acutely impacted our first quarter results. Turning now to our 2025 total company guidance on Slides 7 and 8 of the earnings presentation. We are raising our guidance for revenue, adjusted EBITDA, and earnings per share and increasing the low end of our free cash flow guidance. We now anticipate revenue of approximately $3.1 billion with modestly better revenue assumptions across the business as well as contributions from a slightly earlier close of the Kinectrics acquisition. Accordingly, we're raising our adjusted EBITDA guidance to $565 million to $575 million, up $10 million at the midpoint as the stronger operational performance in government and slightly higher revenue in commercial is partially offset by mix and growth investment, as I previously discussed. These changes to our operating outlook, combined with a lower tax rate and better pension and other income yield an increase in our adjusted EPS guidance to $3.65 to $3.75 per share. This is up about $0.23 at the midpoint compared to our original guidance, with half of the increase driven by operations and half by the nonoperating items I previously discussed. Lastly, we are increasing our free cash flow guidance to $275 million to $285 million, up $10 million at the low end as higher income and benefits from tax legislation are partially offset by slightly higher CapEx. Overall, we had a strong second quarter and are well positioned to meet our increased guidance for the year. With that, I will turn it back to Rex for closing remarks.
Thanks, Mike. Over the past decade as a stand-alone public company, BWXT has invested both organically and inorganically to enhance our capabilities in the nuclear market. We have built significant industrial scale and our customers are increasingly relying on BWXT to meet their needs. We have had a strong start to the year, both financially and strategically. Our backlog is at a record level. Demand across our end markets is accelerating and our intense focus on operational excellence positions us well to continue to drive shareholder value in the years ahead. And with that, we look forward to taking your questions.
Our first question comes from Scott Deuschle with Deutsche Bank.
Mike, the 10-Q flags a $29 million favorable contract adjustment, I think, on nuclear operations. Can you clarify any more what that relates to and if any of that was assumed in the original guide?
Yes. Thanks, Scott. The $29 million, as you mentioned in the 10-Q, relates to one of the Special Materials contracts. As Rex mentioned, we had strong operating performance in Special Materials. Scott, as you know, we look at a number of different potential opportunities as they relate to those contracts. So a portion of that was included in the guide. But I would say it was a bit more favorable than we had originally anticipated. So I would say a part of it we assumed in our original guidance.
Okay. Great. And then, Rex, do you see any opportunity for BWXT to secure some level of content on new build AP1000s that may be built at some point in the U.S.? And if so, what type of content would the company be able to compete for on those reactors?
Yes, I do, Scott. In fact, we have an MOU with Westinghouse to potentially manufacture certain components for the AP1000 in the U.S. market and potentially in other markets. And what we would do there is similar to what we do and CANDU. We're qualified for pressure components, high-pressure components like steam generators, heat exchangers, we could make that reactor pressure vessel in our Cambridge plant. So there's a lot there. And I think as industrial capacity starts to stretch, we might have some really interesting opportunities there.
Okay. And just to clarify, could your content on that potentially be as large as CANDU? Or would it be still materially smaller?
Yes, I'm not sure if I'd go that far. We'll have to see how that unfolds. For CANDU, of course, we typically get all the steam generators, most of the heat exchangers, and other such content. I'd say it's the same kind of scope of equipment, but I don't know if we would run the table like we do at CANDU.
Our next question comes from the line of Jeff Campbell with Seaport.
Congratulations on the strong quarter. I thought I'd start with one kind of high-level question, then I got a specific one for the second. I thought the appointment of Kevin McCoy, the Chief Nuclear Officer was clearly important, but it's not clear to me how you will influence bottlenecks that don't historically reside at BWXT. So any high-level commentary you can provide there is certainly appreciated.
Yes, Jeff, I didn't quite catch the question. Would you be kind enough to repeat it?
Sure. I was saying that I noted Kevin McCoy's appointment as Chief Nuclear Officer with interest, but I wasn't really sure what his mandate will be since BWXT is usually not the point of dragging when we have difficulties getting these projects through. So just any commentary that you can provide on how he's going to influence...
Right. Okay. I understand the question now. So you're quite correct in the way that title is normally used. And let me just say that that's a bit of a holding place for Kevin. The reason for that is that Kevin is seconded to the Department of Defense to help the Deputy Secretary of Defense and the Secretary of the Navy with nuclear shipbuilding. So he remains an executive employee of BWXT, but he is fully under contract to the Navy. And so that's the title that he's holding while he is occupying those positions with the Navy. In the meantime, we promoted Joe Miller up into President of Government operations to replace Kevin. So it's all part of that dynamic.
Okay. Yes, that makes a lot more sense. My other question was Slide 7, the government operations margins of approximately 20.5%. That seems well above prior guidance. I just wonder if you could pinpoint some drivers of this improvement and maybe their durability.
Yes. So GO margin for the quarter was impacted by the EAC for the special materials contract that we just mentioned. We also had some really good pacing of work as well as some of the timing of materials that was good from an overall margin standpoint. Overall, I would say we're comfortable and happy with some of the efficiencies and utilization that we're seeing at the plants. We think we're continuing to focus on that from a margin standpoint to create some long-term sustainability there. We'll see continued strong performance for the rest of the year, and we'll give you more clarity around what we're expecting in '26 next quarter.
Next question comes from the line of Robert Labick with CJS Securities.
Congrats to Mike on his new role. Rex, you mentioned in your prepared remarks that the CNSC recently approved the irradiation of deuterium and lutetium in your target delivery system. Can you discuss the opportunity this presents? What are the next steps, and what will it take to move forward and produce commercial material?
Sure, Bob. Yes, we're doing that in partnership with Laurentis Energy Partners, as I said in the script. The qualification of those products is really up to our partner. They're the ones that have developed the contracts to produce that material for certain clients. And so we have a bit of a passive role there. We did design and deploy that target delivery system. And so it will be a royalty opportunity for us.
Okay. Great. And then just switching gears a little bit for my follow-up. You have a tremendous amount of opportunities ahead of you, talked about the new SMR growth, Pele build-out, et cetera. Talk about capital allocation. How do you prioritize capital into each of these? What are the big amounts of capital that you need to deploy over the next 5 to 10 years for any of these or other opportunities and how you allocate?
Yes. Maybe I'll start and then flip it over to Mike. We've given the broad guidance that 4% for maintenance CapEx, surging up to perhaps 5% or 6% episodically depending on the opportunity. We're doing the Cambridge plant build out right now, which is obviously non-maintenance CapEx, and that's sort of 1% of our sales right now. And so that pushes it up in that 4% to 6% range. And I think that's how we see it. We don't see in the windshield, Bob, any CapEx super cycles like we've been through, at least at the present moment. So I think you'd see it banded in that range, 4% to 6%, as for how we evaluate it, it's obviously a business case. And we've got so many high-quality business cases right now, and so much competition for capital, it's actually pretty tough. But that goes with the abundance of opportunities that we're facing. Maybe I'll pitch it over to Mike for any additional comments.
Yes, Rex, this is right. The only other thing I'd call out is we did raise guidance and expectations for CapEx to 5.5% to 6%. Part of that is driven by some investments we're making around defense fuels related to enrichment. But as Rex mentioned, we see this. And I think we've said before, we anticipate tens of millions of dollars in investments in some of these opportunities, but we don't see the same level of significant CapEx that we may have seen in the past.
Our next question comes from the line of David Strauss with Barclays.
This is Josh Korn on for David. So you've gotten two Navy contracts now in quick succession. How far are you contracted for those Navy programs?
Those contracts have a performance period of up to eight years. It's typical for the delivery of a full ship set to take between six and eight years, depending on whether that's Virginia and Columbia or Ford. So eight years from the time we sign the contract.
Okay. And then I wanted to ask, so with Kinectrics closing a little earlier than you expected, how much did that contribute to the guidance increase? And then in the free cash flow guidance, what are you assuming for working capital?
Yes, we had indicated that Kinectrics would close around midyear. As we discussed, we evaluate various scenarios, so you’re correct that it closed a few weeks earlier than we anticipated. This timing does factor into the increase in our guidance, although it's a smaller part of it. From an earnings per share perspective regarding Kinectrics, the impact is somewhat offset by the added interest expense from the acquisition funding. Therefore, it’s a minor contribution overall. The majority of the guidance increase stems from the timing and pacing of our work as well as our performance in the Government Operations sector. Regarding working capital, while it's not solely related to Kinectrics, we expect our working capital and free cash flow generation to align with our overall business, projecting over 80% free cash flow generation specific to Kinectrics.
Next question comes from the line of Pete Skibitski with Alembic.
It was a strong quarter. Rex, I would like to follow up on Josh's question regarding the two naval reactor contracts from the last six or seven months. Historically, the Navy has had a more consistent annual pace with you, but now we're seeing a faster pace, especially with this recent significant award. Can you share what factors might be motivating the Navy? I’m not sure if this is due to industrial-based funding or wage growth, but I don’t see you as a bottleneck in submarine construction. Could you provide some insight into what is driving these larger awards in such a short timeframe?
Yes, Pete, the recent pricing agreement we announced, worth $2.6 billion, was timely. Unlike the previous agreement, which faced numerous delays due to the complexities arising from COVID, labor issues, and commodity price pressures, this one came through on schedule. The pace of orders related to the Navy's 30-year shipbuilding plan remains consistent. However, there are concerns about whether shipyards can maintain the pace alongside the supply chain. We believe the Navy's strategy will focus on addressing challenges at shipyards while ensuring the supply chain operates effectively. This latest pricing agreement supports that view, as it includes two Virginias per year, Columbia is now in serial production, and the next Ford will follow. It’s essential to note that, for us, the supply chain is staying on track.
Okay. Got it. So don't expect the next one until 2026, it seems like is what we should think?
It depends. Sometimes it's on two-year intervals, sometimes on three. So we'll see how that unfolds with our customer.
Okay. Okay. And just one follow-up for me. In your prepared remarks, you commented about several advanced nuclear fuel opportunities. I feel like in the past, you guys have said that you're not really interested in commercial fuel opportunities. I just want to validate if that's still true; are these fuel opportunities largely the government at this point?
So not exactly. I'd say there's an interesting, smallish, but an interesting demand signal for TRISO fuel that we're responding to, and we can produce that fuel commercially. We're literally the only company that can produce TRISO at any scale. So there's commercial interest, and I expect we'll get a couple of contracts in that area this year. The other comment was around the front end fuel cycle for the defense enrichment program that we're involved with, depending on the scale of that, and how it unfolds, there could be commercial outlets for that material. So I'd say a couple of opportunities there that are interesting to us.
Our next question comes from the line of Andre Madrid with BTIG.
Looking at microreactor, I know a lot of moving pieces there. It looks like Pele is progressing well. I guess, how should we think about that end market in the near to medium term given the progress on Pele, the loss of DRACO, and is there any contribution from JETSON still? Just trying to figure out what the moving pieces are.
Yes, Andre, let me address those points. For Pele, it is progressing as we have discussed, and we are assembling the reactor core. Recently, I met with a senior official at the Pentagon to discuss the path forward for government microreactors. The procurement strategy will be competitive, aiming to place microreactors at several DoD sites, which is what we've always envisioned. We hoped Pele would evolve into a low-rate initial production program with subsequent production programs to follow, and I believe that could happen in a couple of years. As for DRACO, it hasn’t been abandoned. Just to clarify, DARPA has opted out of the joint venture with NASA for developing that nuclear thermal propulsion technology, but NASA’s program is still moving forward. The funding appropriations for DRACO were $175 million from the House and $110 million from the Senate, so we are on track with that technology development. I am quite optimistic about it. Regarding JETSON, it is a smaller program, and we also have other initiatives like fission surface power. From what I'm hearing, NASA is moving quickly on fission surface power, so there’s a lot of activity, and I believe we will play a significant role in some of these areas.
Okay. That's definitely promising, good to hear. And then, I guess, moving in a different direction, just talking about the naval nuclear supply chain more broadly. I think one of your peers talked about the prospect of taking more work off the plates of the shipyards in order to help clear up some of those bottlenecks. Is that something that you guys would ever be interested in doing? Or has it kind of been there, done that, and I don't really want to do that anymore? I know this is something that I think you guys have explored before, but I wasn't sure if you're maybe taking another look at it with fresh eyes.
I'd say generally, it's not a high interest to us if it's not nuclear qualified components, and that work would not be for the most part. So I wouldn't put it at the top of my list.
Got it. Got it. Okay. No, that makes sense. And one more, if I could squeeze it in. I guess, looking at the supply chain, again, to stick on that, any further impacts related to zirconium? What are you guys seeing there? Does it look like it's getting better, getting worse?
Seems to have leveled out. It certainly went through a spike there, and Mike talked about it in his remarks; it impacted us in the first quarter. There was a modest, very minor impact in the second quarter. Just as a reminder, the zirconium price variability is the reason why we don't accept that risk in our contract, so that passes through to the customer. The impact was merely a timing impact related to how we do the percentage complete contract. So that bounces back to us. So I think it's first settled down, and it comes back to us in the end.
Our next question comes from the line of Jed Dorsheimer with William Blair.
You have Mark Shooter on for Jed. Given all the new enthusiasm and the government support, can you try to place a metric on the engagement level you're seeing now versus a quarter ago or a year ago? Maybe on the number of projects you're bidding on actively or maybe an increase in revenue opportunity?
Well, hard to answer that one, Mark. I would say we certainly see high activity in every one of our end markets. Medical has been compounding at 20% per year. The government appetite seems to be stronger than ever. In fact, I've said earlier today that we kind of can outgrow the government business. Commercial power, the opportunities are abundant. Yes, the markets are just strong everywhere, and we certainly haven't experienced a time like this.
I appreciate it. I thought I'd ask. Just switching gears a bit to the TRISO fuel. I think I heard you mention that you expect some contracts by end of the year. Can you wrap that in any kind of unit economics or maybe a capacity? Or can you give us any more color on what we should be expecting there? Is that going to be any significant impact to the financials this or maybe even next year?
Yes, I'd say I don't want to be specific about timing and say I would be a little bit cautious about the scale of those. They're smallish; they're certainly smaller than the Pele fuel contracts. But I think they're interesting because we're beginning to see the precipitation of modest commercial demand for TRISO fuel. So it's exciting strategically. It's not big economically yet.
Next question comes from the line of Jan-Frans Engelbrecht with Baird.
The first question, I just want to start on the reconciliation bill. There's a lot of big dollars across shipbuilding and the support for the nuclear triad. So I just wanted to get your thoughts on how you're thinking about that and any sort of incremental orders that you expect to start to flow to BWXT where it wouldn't have existed if there was no reconciliation bill.
Yes, the reconciliation bill was good for us. There was funding in there for a second Virginia for 2026. There was, if I recall it correctly, $100 million for defense enrichment, which obviously is right in our wheelhouse and what we're working on with the National Nuclear Security Administration; there was funding that was specific to advanced reactors. You can read that as Pele. There was additional funding for the Strategic Capabilities Office. When you stack all that up, I think it was all quite edifying to programs that we had in progress.
Great. And then just a quick follow-up on the BWRX-300; just on the first reactor in Darlington, how should we think about the revenue recognition, sort of when does that peak for the first reactor? And I guess to add to that question, is there a potential for the TVA deployment to sort of leapfrog reactors two to four at Darlington? So just how should we think about those two locations and just the revenue cadence for Reactor 1 on the GE Hitachi design?
Historically, we mentioned that the revenue potential for the X300 is around $100 million, with the revenue spread fairly evenly over a four-year timeframe. This distribution is due to the long-lead nature of the reactor pressure vessel and other components we manufacture. We have received an official order for the project, which has been approved by the provincial government. Regarding the timing at TVA, I cannot confirm if it will advance ahead of reactors two, three, and four at Darlington, but I certainly hope it will proceed quickly. You can view that opportunity as potentially adding four more X300 units on top of the three at Darlington. It continues to be a thrilling prospect for us. I would speculate that the first reactor at TVA might fall somewhere in the middle of this timeline.
And our next question comes from the line of Michael Ciarmoli from Truist Securities.
Nice results for the super merchant supplier, Rex. Just for guidance this year, I know timing is always challenging to predict, but the guidance suggests that GO revenues could actually decline in the second half year-over-year. You've been assessing the EBITDA margin run rate, and while you received a positive EAC, that second half run rate might be below 20%. This hasn't happened in quite some time. Was it simply a matter of timing? Is there something affecting the mix of these newer programs? Should we expect more cost-plus contracts to come in? What can you share with us regarding that weaker second half?
Yes, I would say I don't think we're seeing a major shift in overall mix across the contract portfolio. So what I would say is we signed a pricing agreement that we mentioned a little ahead of schedule. That had a number of advanced material procurements that came into the quarter that we weren't expecting that typically would be in the back half of the year. In addition, when you look at the special materials contract performance, typically, the fourth quarter is a very strong quarter for us. In a lot of cases, we're seeing strong performance at that point in the year. We see and we're able to get very confident in kind of our contract performance in Q2, which is where you're seeing outsized growth in the quarter. When we look at the rest of the year, I think the way that we look at it, we feel confident in where we'll land. I don't think there's anything individually to call out too much around overall revenue. I would just say that we're seeing a number of things hit earlier in the year than we typically do.
I'll just add a note to what Mike mentioned. The operating condition of the plants is good. We have implemented a focused campaign around operational excellence that covers various aspects such as factory throughput, lead time, cost of poor quality, and the price of nonconformance, which is the name of our program. The plants in Cambridge and throughout Canada, especially in our NOG complex, are performing quite well. We experienced strong over-performance in the first half, and while we expect some normalization in the second half, we are optimistic about our operational performance. There is no decline from that perspective.
Okay. Okay. And then just kind of on that topic. Maybe the first year commercial, it sounds like you've got good line of sight to that field services. I thought that was good color, Mike, providing kind of a percent of revenue. Presumably, you get a pickup in field services, and that drives the margin strength in commercial second half?
That's correct. We experienced a seasonal decline, as Q2 is typically a strong quarter for us. However, we saw a notable drop to 10% of revenue in that mix. We are optimistic about how the rest of the year will unfold and are confident about our prospects in field services and components margins for the upcoming quarters.
And our last question comes from the line of Ron Epstein with BAML.
Maybe just a couple of quick ones. One, when you look at the growth in the backlog, it bumped up a lot. How much of that is because of the acquisition and how much of that is organic?
Yes. From the majority of that, it's going to be organic. If you look at ultimately, our book-to-bill for this quarter was 2.2. We had really about $240 million-ish of backlog associated with the acquisitions, but the majority of it was organic.
Got it. All right. Great. That's super. And then one more. We've heard some companies talking this quarter about shortages of critical minerals. Has that been an issue for you guys? Do you see it as a potential issue? And how are you mitigating it? Or is it just not an issue at all?
Yes, I'll take that one, Ron. We're not experiencing much pressure from that. The zirconium pricing you noticed in the first quarter was a result of that issue, but it seems to be stabilizing now. As I mentioned earlier, aside from that, we handle our commodity risk effectively and aren't significantly impacted by critical minerals. It's not having a major effect on us.
Yes. I would like to clarify that we are not experiencing any difficulties in obtaining the actual raw materials. In terms of pricing, we have mentioned previously that our agreements generally allow us to secure pricing for about 70% of our overall materials purchases. This is achieved through firm vendor quotes or extended ordering periods, which enables us to effectively manage our costs.
That concludes the question-and-answer session. I would like to turn the call back over to Mr. Chase Jacobson for closing remarks.
Thank you. Thanks, everybody, for joining today. We look forward to seeing many of you and speaking with you in the upcoming weeks at investor events or on the phone. If you have any questions, please feel free to reach out to me at investors bwxt.com. Thank you.
Ladies and gentlemen, that concludes today's call. Thank you all for joining, and you may now disconnect.